CRMD
Cormedix Inc
NASDAQ · Pharmaceuticals
$7.69
+0.34 (+4.63%)
Income Statement
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Revenue | 58.18M | 151.82M | 142.81M | 140.45M |
| Net Income | -23,999,143 | 25.07M | 23.58M | 28.46M |
| EPS | — | — | — | — |
| Profit Margin | -41.2% | 16.5% | 16.5% | 20.3% |
| Rev Growth | +511.6% | +9.9% | -6.7% | -6.8% |
Balance Sheet
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| Total Debt | 0 | 50.32M | 44.84M | 51.37M |
| Total Equity | — | 528.35M | 516.77M | 505.47M |
| D/E Ratio | — | 0.10 | 0.09 | 0.10 |
Cash Flow
| FY 2026 | FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|---|
| EBITDA | -29,018,005 | 47.08M | 40.68M | 43.83M |
| Free Cash Flow | — | 14.58M | 22.25M | 13.22M |